Jonathan McNeill - 14 Jun 2022 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Senior Vice President of Business Development
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
14 Jun 2022
Transactions value $
-$2,495
Form type
4
Filing time
15 Jun 2022, 20:04:34 UTC
Previous filing
14 Mar 2022
Next filing
06 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Disposed to Issuer -$2,494 -504 -0.83% $4.95 59,962 14 Jun 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2 Includes 34,907 unvested RSUs.

Remarks:

Senior Vice President of Business Development